Physician profile
Robert T Bechtel
NPI 1952374472
$1,176.59
in general payments reported to CMS, 2019-2025
13 companies · $63.61 in 2025
The $63.61 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $120 · 2021: $179 · 2022: $198 · 2023: $103 · 2024: $95.75 · 2025: $63.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $314.81 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $237.70 | 2019-2021 | |
| Abbvie INC. | $194.79 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $116.26 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $95.99 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.85 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $56.17 | 2023-2025 | Vyzulta |
| Alcon Vision LLC | $30.42 | 2022 | |
| Oyster Point Pharma, INC. | $19.88 | 2022 | |
| Mallinckrodt Enterprises LLC | $18.10 | 2019 | |
| Shire North American Group INC | $17.03 | 2019 | |
| Akorn Operating Company LLC | $16.76 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bechtel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.